If vitiligo involves most of the body, it might be easier to depigment the normal remaining
skin rather than to attempt repigmentation. We reviewed the literature to date regarding …

As an immune-response modifier, imiquimod can bind to Toll-like receptors on immune cells
and enhance innate and adaptive immune responses, exerting potential antitumor and …

Background Vitiligo is characterized by the death of melanocytes in the skin. This is
associated with the presence of T cell infiltrates in the lesional borders. However, at present …

Depigmentation therapy in vitiligo is an option in those with extensive vitiligo who have
failed to respond to medical therapy and have obvious cosmetic disfigurement due to …

Background Condylomata acuminata (genital warts) is the most common sexually
transmitted disease, and imiquimod is the sole FDA-approved medication for combating this …

BACKGROUND Ultraviolet radiation (UVR) contributes to the vast majority of nonmelanoma
skin cancer (NMSC). As the incidence of NMSC continues to rise, topical therapies will be …

Imiquimod is an immunomodulator of the imidazoquinoline group which possesses antiviral
and antitumour activities. Although its mechanism of action has not been entirely elucidated …

A 69-year-old man presented with a black irregular patch on his left cheek. Skin biopsy
revealed lentigo maligna melanoma in situ. He was treated via partial excision of the …

Gefitinib is a tyrosine kinase inhibitor that targets and inhibits epidermal growth factor
receptors. It was initially used to treat non-small cell lung cancer but has increasingly been …

Introduction Imiquimod plays an important role in the management of condyloma and
premalignant lesions. Successively, an increase of hypopigmented lesions following …